<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781781</url>
  </required_header>
  <id_info>
    <org_study_id>ALOTIRNE-EC06007</org_study_id>
    <secondary_id>2007-006440-22</secondary_id>
    <nct_id>NCT00781781</nct_id>
  </id_info>
  <brief_title>Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning</brief_title>
  <official_title>Multicenter, Openlabel, Phase II Intergroups (GELTAMO/GETH) Trial, on the Use of Alemtuzumab for Unrelated Donor Reduced Intensity Conditioning Allogenic Transplant in Hematological Malignancies Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CABYC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CABYC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the results of incidence and severity of acute and
      chronic GVHD, (see addendum II) and of disease free survival with Alemtuzumab use
      (MabCampath®) in haematopoietic transplant of unrelated donor with reduced intensity
      conditioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will be assigned to one of the two dosing schedules and total dose of drug
      envisaged in the study. The assignation to conventional or reduced Alemtuzumab (MabCampath)
      dose will be done depending on the age and risk of suffering GVHD, in function of variables
      coming from general experience.

      High risk of GVHD criteria:

      Gender incompatibility: male patient of female donor. HLA incompatibility: non identical high
      resolution typing in HLA A, B, C, DRB1, DQB1 (identity less than 10/10 alleles by high
      resolution) Age of patient more or equal than 55 years

      Conventional doses in high risk (at least one criterion of GVHD high risk):

      100 mg de Alemtuzumab IV total dose in 5, 20 mg fractions, days -8, -7, -6, -5 and -4.

      Reduced dose in low risk cases (no criteria of GVHD high risk):

      50 mg de Alemtuzumab IV total dose en 5 fractions of 10 mg, days -5, -4, -3, -2 and -1.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit the number of patients established in the study protocol (34 of 40)
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze the results of incidence and severity of acute and chronic GVHD</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High risk patients (at least one GVHD high risk criterion):
Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Risk patients (no GVHD high risk criterion):
Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>MabCampath</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with haematological or lymphoid malignancies with allogenic transplantation
             indication:

               -  High risk follicular NHL, mantle HHC and other low grade NHC (e.g
                  lymphoplasmacytic, extranodal or from marginal zone).

                    1. Disease that does not obtain a CR with Fludarabine or antiCD-20 including
                       chemotherapy.

                    2. Relapse after autologous transplant.

                    3. Non candidates to autologous transplant in 2nd CR (e.g. mobilization
                       failure, or persistent marrow infiltrate).

               -  Poor prognosis chronic lymphoblastic leukaemia (CLL): Del 11q, Del 17p, complex
                  cariotype; B symptoms, progressive low cell count by marrow infiltration,
                  lymphocytosis or enlarged lymph nodes, or progressive spleen growth.

               -  High grade lymphoma transformed from a low grade non Hodgkin's lymphoma or from a
                  chronic lymphocitic leukaemia

               -  High risk T peripheral lymphoma, with IPI &gt; or = 2, non susceptible of autologous
                  transplant, or relapsed after autologous transplant

               -  Primarily refractory high risk Hodgkin's disease, relapse in patients not
                  susceptible of autologous transplant or relapse after autologous transplant.

               -  High risk acute mieloblastic leukaemia (AML) in 1st CR, or AMC &gt; or = 2 CR,
                  including AML after MDS and secondary AML.

               -  High risk acute lymphoblastic leukaemia (ALL) because of poor response to
                  induction chemotherapy (&gt;10% blasts day +14 or no RC day +28-35), or by
                  cytogenetic criteria: Ph+ or 11q23.

               -  High risk myelodisplastic syndromes (SMD) type RAEB-1 or AREB-2 with IPSS &gt;Int-1.

          -  For the inclusion in transplant patients with ALL or AML must be in CR, patients with
             MDS must have &lt;10% blasts en la BM, and patients with lymphoid malignancies must show
             previous chemosensitivity, with PR or CR.

          -  Patients 40 to 65 years old. Patients outside this age range could be included
             according to participating centres criteria.

          -  Patients in the study population lacking a compatible related donor, and with a
             possible compatible unrelated donor (&gt;=9/10 by 10 alleles high resolution typing:
             HLA-A, B, C, DRB1, DQB1) to assign the patients to a risk in subgroup.

          -  Signed informed consent.

          -  Not fulfilling any of the following exclusion criteria.

        Exclusion Criteria:

          -  Liver (≥ x3 UNL), kidney (GF &lt;40ml/min), cardiac (LVEF &lt;40%) or respiratory (DLCO &amp;
             FVC &lt;40% of expected) function tests impairment.

          -  HIV injection.

          -  Absence of signed informed consent.

          -  Progressive disease previous to transplant or not fulfilling the above mentioned
             response criteria.

          -  Other co-morbidities that contraindicate CT.

          -  Pregnant and/or breast-feeding women or with pregnancy risk by inadequate
             contraception.

          -  Life expectancy &lt;6 months.

          -  Mental or psychiatric deficiency impeding adequate understanding and consent to
             therapy

          -  Hypersensitivity as shown by anaphylactic reaction to any of the DRUGS used in the
             trial.

          -  Active infectious process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Duarte, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>ICO Bellvitge. Hospital Duran i Reynals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial.</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall de Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloid and Lymphoid malignances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

